Loading…

Phosphorylation of estrogen receptor α blocks its acetylation and regulates estrogen sensitivity

Estrogen receptor (ER) alpha is mutated (lysine 303 to arginine, K303R) in approximately one third of premalignant breast hyperplasias, which renders breast cancer cells expressing the mutant receptor hypersensitive for proliferation in response to low doses of estrogen. It is known that ERalpha is...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2004-12, Vol.64 (24), p.9199-9208
Main Authors: YUKUN CUI, MAO ZHANG, PESTELL, Richard, CURRAN, Edward M, WELSHONS, Wade V, FUQUA, Suzanne A. W
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3306-ad2c1b5b2e80cf2d5fe4f1084f9c25420f8b0c8903c66520217519a2f85bc2923
cites cdi_FETCH-LOGICAL-c3306-ad2c1b5b2e80cf2d5fe4f1084f9c25420f8b0c8903c66520217519a2f85bc2923
container_end_page 9208
container_issue 24
container_start_page 9199
container_title Cancer research (Chicago, Ill.)
container_volume 64
creator YUKUN CUI
MAO ZHANG
PESTELL, Richard
CURRAN, Edward M
WELSHONS, Wade V
FUQUA, Suzanne A. W
description Estrogen receptor (ER) alpha is mutated (lysine 303 to arginine, K303R) in approximately one third of premalignant breast hyperplasias, which renders breast cancer cells expressing the mutant receptor hypersensitive for proliferation in response to low doses of estrogen. It is known that ERalpha is posttranslationally modified by protein acetylation and phosphorylation by a number of secondary messenger signaling cascades. The K303R ERalpha mutation resides at a major protein acetylation site adjacent to a potential protein kinase A (PKA) phosphorylation site at residue 305 within the hinge domain of the receptor. Mutation of this phosphorylation site to aspartic acid to mimic constitutive phosphorylation blocks acetylation of the K303 ERalpha site and generates an enhanced transcriptional response similar to that seen with the naturally occurring K303R mutant receptor. Activation of PKA signaling by the cell-permeable cyclic AMP (cAMP) analog 8-bromo-cAMP further enhances estrogen sensitivity of the mutant receptor, whereas a specific PKA inhibitor antagonizes this increase. We propose that the hypersensitive ERalpha mutant breast cancer phenotype involves an integration of coupled acetylation and phosphorylation events by upstream signaling molecules.
doi_str_mv 10.1158/0008-5472.CAN-04-2126
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67179841</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17293277</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3306-ad2c1b5b2e80cf2d5fe4f1084f9c25420f8b0c8903c66520217519a2f85bc2923</originalsourceid><addsrcrecordid>eNqFkU1OwzAQhS0EoqVwBFA2sEsZO3bsLKuKP6kCFrC2HMduA2lc7BSpx-IinAlXDXTJavSk782M3kPoHMMYYyauAUCkjHIynk4eU6ApwSQ_QEPMMpFyStkhGv4xA3QSwluUDAM7RgPMcqCkyIZIPS9cWC2c3zSqq12bOJuY0Hk3N23ijTarzvnk-yspG6ffQ1J3IVHadL-4aquIzddRmrB3BtOGuqs_625zio6saoI56-cIvd7evEzv09nT3cN0Mkt1lkGeqopoXLKSGAHakopZQy0GQW2hCaMErChBiwIyneeMAMGc4UIRK1ipSUGyEbra7V1597GOn8hlHbRpGtUatw4y55gXguJ_QcxjMoTzCLIdqL0LwRsrV75eKr-RGOS2BLkNWG4DlrEECVRuS4i-i_7Aulyaau_qU4_AZQ-ooFVjvWp1HfZcnnGBAbIfn32RVA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17293277</pqid></control><display><type>article</type><title>Phosphorylation of estrogen receptor α blocks its acetylation and regulates estrogen sensitivity</title><source>EZB Electronic Journals Library</source><creator>YUKUN CUI ; MAO ZHANG ; PESTELL, Richard ; CURRAN, Edward M ; WELSHONS, Wade V ; FUQUA, Suzanne A. W</creator><creatorcontrib>YUKUN CUI ; MAO ZHANG ; PESTELL, Richard ; CURRAN, Edward M ; WELSHONS, Wade V ; FUQUA, Suzanne A. W</creatorcontrib><description>Estrogen receptor (ER) alpha is mutated (lysine 303 to arginine, K303R) in approximately one third of premalignant breast hyperplasias, which renders breast cancer cells expressing the mutant receptor hypersensitive for proliferation in response to low doses of estrogen. It is known that ERalpha is posttranslationally modified by protein acetylation and phosphorylation by a number of secondary messenger signaling cascades. The K303R ERalpha mutation resides at a major protein acetylation site adjacent to a potential protein kinase A (PKA) phosphorylation site at residue 305 within the hinge domain of the receptor. Mutation of this phosphorylation site to aspartic acid to mimic constitutive phosphorylation blocks acetylation of the K303 ERalpha site and generates an enhanced transcriptional response similar to that seen with the naturally occurring K303R mutant receptor. Activation of PKA signaling by the cell-permeable cyclic AMP (cAMP) analog 8-bromo-cAMP further enhances estrogen sensitivity of the mutant receptor, whereas a specific PKA inhibitor antagonizes this increase. We propose that the hypersensitive ERalpha mutant breast cancer phenotype involves an integration of coupled acetylation and phosphorylation events by upstream signaling molecules.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>DOI: 10.1158/0008-5472.CAN-04-2126</identifier><identifier>PMID: 15604293</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Acetylation ; Antineoplastic agents ; Biological and medical sciences ; Cell Line, Tumor ; Cyclic AMP-Dependent Protein Kinases - metabolism ; Estrogen Receptor alpha - antagonists &amp; inhibitors ; Estrogen Receptor alpha - metabolism ; Estrogens - physiology ; Humans ; Medical sciences ; Pharmacology. Drug treatments ; Phenotype ; Phosphorylation ; Signal Transduction - physiology</subject><ispartof>Cancer research (Chicago, Ill.), 2004-12, Vol.64 (24), p.9199-9208</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3306-ad2c1b5b2e80cf2d5fe4f1084f9c25420f8b0c8903c66520217519a2f85bc2923</citedby><cites>FETCH-LOGICAL-c3306-ad2c1b5b2e80cf2d5fe4f1084f9c25420f8b0c8903c66520217519a2f85bc2923</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=16378100$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15604293$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>YUKUN CUI</creatorcontrib><creatorcontrib>MAO ZHANG</creatorcontrib><creatorcontrib>PESTELL, Richard</creatorcontrib><creatorcontrib>CURRAN, Edward M</creatorcontrib><creatorcontrib>WELSHONS, Wade V</creatorcontrib><creatorcontrib>FUQUA, Suzanne A. W</creatorcontrib><title>Phosphorylation of estrogen receptor α blocks its acetylation and regulates estrogen sensitivity</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>Estrogen receptor (ER) alpha is mutated (lysine 303 to arginine, K303R) in approximately one third of premalignant breast hyperplasias, which renders breast cancer cells expressing the mutant receptor hypersensitive for proliferation in response to low doses of estrogen. It is known that ERalpha is posttranslationally modified by protein acetylation and phosphorylation by a number of secondary messenger signaling cascades. The K303R ERalpha mutation resides at a major protein acetylation site adjacent to a potential protein kinase A (PKA) phosphorylation site at residue 305 within the hinge domain of the receptor. Mutation of this phosphorylation site to aspartic acid to mimic constitutive phosphorylation blocks acetylation of the K303 ERalpha site and generates an enhanced transcriptional response similar to that seen with the naturally occurring K303R mutant receptor. Activation of PKA signaling by the cell-permeable cyclic AMP (cAMP) analog 8-bromo-cAMP further enhances estrogen sensitivity of the mutant receptor, whereas a specific PKA inhibitor antagonizes this increase. We propose that the hypersensitive ERalpha mutant breast cancer phenotype involves an integration of coupled acetylation and phosphorylation events by upstream signaling molecules.</description><subject>Acetylation</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Cell Line, Tumor</subject><subject>Cyclic AMP-Dependent Protein Kinases - metabolism</subject><subject>Estrogen Receptor alpha - antagonists &amp; inhibitors</subject><subject>Estrogen Receptor alpha - metabolism</subject><subject>Estrogens - physiology</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Phenotype</subject><subject>Phosphorylation</subject><subject>Signal Transduction - physiology</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNqFkU1OwzAQhS0EoqVwBFA2sEsZO3bsLKuKP6kCFrC2HMduA2lc7BSpx-IinAlXDXTJavSk782M3kPoHMMYYyauAUCkjHIynk4eU6ApwSQ_QEPMMpFyStkhGv4xA3QSwluUDAM7RgPMcqCkyIZIPS9cWC2c3zSqq12bOJuY0Hk3N23ijTarzvnk-yspG6ffQ1J3IVHadL-4aquIzddRmrB3BtOGuqs_625zio6saoI56-cIvd7evEzv09nT3cN0Mkt1lkGeqopoXLKSGAHakopZQy0GQW2hCaMErChBiwIyneeMAMGc4UIRK1ipSUGyEbra7V1597GOn8hlHbRpGtUatw4y55gXguJ_QcxjMoTzCLIdqL0LwRsrV75eKr-RGOS2BLkNWG4DlrEECVRuS4i-i_7Aulyaau_qU4_AZQ-ooFVjvWp1HfZcnnGBAbIfn32RVA</recordid><startdate>20041215</startdate><enddate>20041215</enddate><creator>YUKUN CUI</creator><creator>MAO ZHANG</creator><creator>PESTELL, Richard</creator><creator>CURRAN, Edward M</creator><creator>WELSHONS, Wade V</creator><creator>FUQUA, Suzanne A. W</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20041215</creationdate><title>Phosphorylation of estrogen receptor α blocks its acetylation and regulates estrogen sensitivity</title><author>YUKUN CUI ; MAO ZHANG ; PESTELL, Richard ; CURRAN, Edward M ; WELSHONS, Wade V ; FUQUA, Suzanne A. W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3306-ad2c1b5b2e80cf2d5fe4f1084f9c25420f8b0c8903c66520217519a2f85bc2923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Acetylation</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Cell Line, Tumor</topic><topic>Cyclic AMP-Dependent Protein Kinases - metabolism</topic><topic>Estrogen Receptor alpha - antagonists &amp; inhibitors</topic><topic>Estrogen Receptor alpha - metabolism</topic><topic>Estrogens - physiology</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Phenotype</topic><topic>Phosphorylation</topic><topic>Signal Transduction - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YUKUN CUI</creatorcontrib><creatorcontrib>MAO ZHANG</creatorcontrib><creatorcontrib>PESTELL, Richard</creatorcontrib><creatorcontrib>CURRAN, Edward M</creatorcontrib><creatorcontrib>WELSHONS, Wade V</creatorcontrib><creatorcontrib>FUQUA, Suzanne A. W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YUKUN CUI</au><au>MAO ZHANG</au><au>PESTELL, Richard</au><au>CURRAN, Edward M</au><au>WELSHONS, Wade V</au><au>FUQUA, Suzanne A. W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phosphorylation of estrogen receptor α blocks its acetylation and regulates estrogen sensitivity</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>2004-12-15</date><risdate>2004</risdate><volume>64</volume><issue>24</issue><spage>9199</spage><epage>9208</epage><pages>9199-9208</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>Estrogen receptor (ER) alpha is mutated (lysine 303 to arginine, K303R) in approximately one third of premalignant breast hyperplasias, which renders breast cancer cells expressing the mutant receptor hypersensitive for proliferation in response to low doses of estrogen. It is known that ERalpha is posttranslationally modified by protein acetylation and phosphorylation by a number of secondary messenger signaling cascades. The K303R ERalpha mutation resides at a major protein acetylation site adjacent to a potential protein kinase A (PKA) phosphorylation site at residue 305 within the hinge domain of the receptor. Mutation of this phosphorylation site to aspartic acid to mimic constitutive phosphorylation blocks acetylation of the K303 ERalpha site and generates an enhanced transcriptional response similar to that seen with the naturally occurring K303R mutant receptor. Activation of PKA signaling by the cell-permeable cyclic AMP (cAMP) analog 8-bromo-cAMP further enhances estrogen sensitivity of the mutant receptor, whereas a specific PKA inhibitor antagonizes this increase. We propose that the hypersensitive ERalpha mutant breast cancer phenotype involves an integration of coupled acetylation and phosphorylation events by upstream signaling molecules.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>15604293</pmid><doi>10.1158/0008-5472.CAN-04-2126</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-5472
ispartof Cancer research (Chicago, Ill.), 2004-12, Vol.64 (24), p.9199-9208
issn 0008-5472
1538-7445
language eng
recordid cdi_proquest_miscellaneous_67179841
source EZB Electronic Journals Library
subjects Acetylation
Antineoplastic agents
Biological and medical sciences
Cell Line, Tumor
Cyclic AMP-Dependent Protein Kinases - metabolism
Estrogen Receptor alpha - antagonists & inhibitors
Estrogen Receptor alpha - metabolism
Estrogens - physiology
Humans
Medical sciences
Pharmacology. Drug treatments
Phenotype
Phosphorylation
Signal Transduction - physiology
title Phosphorylation of estrogen receptor α blocks its acetylation and regulates estrogen sensitivity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T11%3A45%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phosphorylation%20of%20estrogen%20receptor%20%CE%B1%20blocks%20its%20acetylation%20and%20regulates%20estrogen%20sensitivity&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=YUKUN%20CUI&rft.date=2004-12-15&rft.volume=64&rft.issue=24&rft.spage=9199&rft.epage=9208&rft.pages=9199-9208&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/10.1158/0008-5472.CAN-04-2126&rft_dat=%3Cproquest_cross%3E17293277%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3306-ad2c1b5b2e80cf2d5fe4f1084f9c25420f8b0c8903c66520217519a2f85bc2923%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17293277&rft_id=info:pmid/15604293&rfr_iscdi=true